What a spinal bone growth stimulator is
A spinal bone growth stimulator is a prescription medical device used as an adjunct after spinal fusion surgery or, in some cases, after a failed fusion. Its role is to generate electrical, electromagnetic, magnetic, or ultrasonic signals around the fusion site to support osteogenesis, the biological process of new bone formation.
It is not a substitute for implants, bone graft material, surgical technique, smoking cessation, nutrition, or postoperative restrictions. The practical issue is patient selection. Evidence and coverage policies generally focus on patients with a higher risk of pseudarthrosis, rather than routine use after every fusion procedure.
In the United States, the regulatory and policy framework has become more specific. FDA codified a classification for non-invasive bone growth stimulators in 21 CFR 890.5870, describing them as prescription devices used externally to promote osteogenesis as an adjunct to fracture fixation and spinal fusion, or as treatment for established nonunions or failed fusions. On April 16, 2026, FDA issued a final order reclassifying non-invasive bone growth stimulators under product codes LOF and LPQ from class III to class II with special controls, effective May 18, 2026. That change affects the device pathway, but it should not be read as a blanket clinical recommendation for every spine case.
For readers following broader spinal devices, bone growth stimulation sits between implant performance, biologics, reimbursement policy, and patient adherence. The device may be straightforward to wear, but the decision to prescribe it is usually tied to surgical risk factors and payer documentation.
Why stimulators are considered after spinal fusion
Spinal fusion is intended to create a solid bony bridge between vertebrae. When fusion does not occur as expected, the result may be described as nonunion, failed fusion, or pseudarthrosis. Not every radiographic nonunion causes symptoms, and not every painful outcome is caused by a fusion problem. Still, lack of solid fusion can contribute to persistent pain, hardware stress, revision surgery, and uncertainty in long-term outcomes.
Bone growth stimulators are considered when the clinical team believes the patient has an elevated risk of incomplete fusion. Long-standing Medicare national coverage language covers electrical osteogenic stimulators for failed fusion when at least nine months have elapsed since the last surgery. It also covers adjunctive use in spinal fusion surgery for patients at high risk of pseudarthrosis because of a previously failed spinal fusion at the same site or a multiple-level fusion. CMS defines a multiple-level fusion in that policy as involving three or more vertebrae.
Private payers often use similar concepts but may define risk factors in more detail. Examples may include revision fusion, multilevel fusion, current tobacco use, osteoporosis or osteopenia, diabetes, long-term corticosteroid exposure, immunocompromise, systemic vascular disease, or other factors that can impair bone healing. Exact coverage language varies, so the operative note, diagnosis, imaging, number of levels, and risk-factor documentation often matter as much as the prescription itself.
Main device approaches and how they differ
The term spinal bone growth stimulator can refer to several technologies. They share the same broad objective, supporting bone formation, but differ in how energy is delivered, when they are used, and what the patient must do at home.
| Approach | How it is delivered | Typical spine context | Practical consideration |
|---|---|---|---|
| Direct current stimulation | Implanted electrodes deliver current at the fusion site | Placed during surgery in selected fusion cases | Invasive and tied to the surgical procedure |
| Pulsed electromagnetic field stimulation | An external coil or wearable system creates an electromagnetic field | Used after surgery in selected high-risk fusion patients, depending on labeling | Requires consistent daily use for the prescribed period |
| Capacitive coupling stimulation | Skin electrodes are positioned around the target area to create a low-energy electrical field | Used after lumbar fusion in some FDA-approved systems | Electrode placement, skin tolerance, battery management, and adherence are central |
| Low-intensity pulsed ultrasound | Ultrasound energy is applied externally | More commonly discussed for certain fracture nonunions than for spinal fusion | Spinal indications should be checked against the specific device label |
FDA device summaries show why product-specific labeling matters. The Xstim Spine Fusion Stimulator, approved on February 9, 2024, is a non-invasive capacitively coupled device for adult patients after one- or two-level lumbar fusion, with FDA’s public overview describing home use for nine months. The ActaStim-S Spine Fusion Stimulator labeling similarly describes a non-invasive adjunct electrical treatment for primary lumbar spinal fusion surgery for one or two levels in adult patients. These examples are not interchangeable with all other systems; they show why clinicians and device teams should read the exact indication, patient population, contraindications, warnings, and daily-use instructions for the prescribed model.
What current evidence and policy support
The evidence base is supportive in selected settings, but it is not unlimited. The 2014 guideline update for lumbar fusion procedures from neurosurgical guideline authors identified three routinely used electrical stimulation categories: direct current stimulation, pulsed electromagnetic field stimulation, and capacitive coupled electrical stimulation. It found no new evidence that overturned earlier recommendations.
In simplified terms, earlier guidance supported considering direct current stimulation or capacitive coupling in high-risk patients undergoing posterolateral lumbar fusion, and pulsed electromagnetic field stimulation in high-risk patients undergoing interbody fusion. The same update also emphasized that some evidence remained limited and that not all technologies had strong data for every indication.
That distinction matters for industry readers. Fusion rate is a radiographic endpoint, while pain relief, function, return to work, and avoidance of revision surgery are clinical outcomes. A device can be associated with improved fusion in a defined population without proving broad improvement across all patient-centered outcomes. For this reason, careful articles and policies avoid saying that a stimulator guarantees fusion or guarantees symptom relief.
The North American Spine Society maintains coverage recommendations intended to help payers, providers, and patients interpret evidence and coverage positions. Its public coverage page lists Electrical Stimulation for Bone Healing as a February 2025 coverage recommendation and notes that its coverage documents are reviewed periodically. Because coverage recommendations, payer policies, and FDA labeling can change at different speeds, the practical decision in 2026 should not be based on one source alone. It requires comparison of device labeling, surgical indication, patient risk profile, imaging, payer rules, and clinician judgment.
What changed with FDA reclassification in 2026
FDA’s 2026 final order is a regulatory milestone for non-invasive bone growth stimulators, not a simple clinical endorsement. Reclassification from class III to class II with special controls means that qualifying non-invasive devices may be reviewed through a less burdensome premarket notification pathway rather than the premarket approval pathway used for higher-risk devices. FDA stated that special controls are needed to provide reasonable assurance of safety and effectiveness.
Those special controls are central to the change. Under 21 CFR 890.5870, clinical data must demonstrate that the device performs as intended under anticipated conditions of use, and imaging data must demonstrate fusion at the treatment site. Non-clinical performance testing, labeling, electrical safety, electromagnetic compatibility, software validation where applicable, and user instructions remain part of the safety-and-effectiveness framework. See also: Implants.
For manufacturers, the change may reduce regulatory burden and potentially support more timely market entry. For clinicians and hospitals, it may increase the need to compare devices carefully because class II status does not make all systems clinically identical. For patients, the rule remains familiar: the device should be used only as prescribed, for the intended indication, and with attention to warnings and follow-up imaging.
Practical questions before prescribing or using a stimulator
A spinal bone growth stimulator is often used at home, so real-world value depends on correct selection and adherence. Before prescribing or dispensing a device, the care team should be able to answer several practical questions.
- What is the indication? Is the device being used after a primary lumbar fusion, after revision surgery, or because imaging suggests failed fusion?
- Which levels are being treated? The prescribed device should match the spinal region and number of levels described in its labeling.
- What risk factors justify use? Multilevel fusion, previous failed fusion, tobacco exposure, metabolic bone disease, diabetes, corticosteroid use, or other healing risks should be documented if relevant.
- What is the daily schedule? Some systems require all-day use, while others may have shorter daily treatment windows. The patient should know the expected duration before leaving the clinic.
- What device-specific warnings apply? Pacemakers, implanted cardioverters, pregnancy, skin reactions, infection, cancer history, renal disease, osteoporosis, and other conditions may require specific review depending on the device label.
- How will adherence be tracked? Many failures are practical rather than technological: missed sessions, electrode irritation, battery problems, incorrect placement, or misunderstanding instructions.
Patients should also understand what the device cannot do. It cannot compensate for continued nicotine use if the surgeon has advised cessation. It cannot stabilize a mechanically inadequate construct. It cannot make up for missed follow-up visits or imaging. It is best understood as one part of a fusion-healing plan.
Documentation and reimbursement considerations
Coverage is not guaranteed simply because a surgeon writes a prescription. Payers may require proof of skeletal maturity, operative details, fusion levels, prior failed fusion at the same site, elapsed time since surgery, radiology reports, or specific comorbidities that increase nonunion risk. Some policies distinguish between invasive and non-invasive stimulation, and between electrical and ultrasound technologies.
For failed spinal fusion, Medicare’s national coverage language refers to a minimum of nine months after the last surgery. For adjunctive use at the time of spinal fusion, the same national policy centers on high-risk pseudarthrosis related to prior failed fusion at the same site or multiple-level fusion. Commercial policies may be broader or narrower. Device suppliers, billing teams, and clinicians should not assume that one payer’s approval criteria apply to another payer.
From an industry perspective, the documentation trend is clear: coverage decisions are increasingly tied to explicit risk criteria and evidence categories. Device companies and providers that educate patients only on comfort and convenience may miss the more important issue: whether the prescription is clinically and administratively well supported.
Frequently asked questions
Does a spinal bone growth stimulator replace spinal fusion surgery?
No. It is an adjunct to primary treatment, not a replacement for surgical fixation, bone grafting, implant selection, or postoperative restrictions. It is intended to support bone formation in the environment created by the fusion procedure.
Is a bone growth stimulator used for every fusion patient?
No. Current evidence and coverage policies generally emphasize selected patients, especially those at higher risk of pseudarthrosis or those with a failed fusion. Routine use in all patients is not the central message of the major policy and guideline sources.
How long does a patient use the device?
Duration depends on the device and the prescription. FDA’s public overview for one lumbar capacitive-coupling device describes use at home for nine months, but other devices may have different schedules. The prescribing surgeon and device instructions should be the controlling sources.
Are all spinal bone growth stimulators the same?
No. Direct current, pulsed electromagnetic field, capacitive coupling, and ultrasound systems differ in delivery method, indication, evidence base, and labeling. A device cleared or approved for one indication should not be assumed appropriate for another spinal region or patient group.
What should patients ask if they have a pacemaker or are pregnant?
They should tell the surgeon and device representative before use. Some device labeling calls for individual assessment for patients with pacemakers or cardioverters, and some labeling states that safety and effectiveness in pregnancy have not been studied. The correct answer is device-specific medical review, not general reassurance.